Collagenous colitis, eosinophilic colitis, and neutropenic colitis.

Surg Clin North Am

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Published: October 1993

Neutropenic colitis is a complication of the treatment of hematologic malignancies and, less commonly, of other disease entities. The septic, inflammatory process has a predilection for the terminal ileum and right colon. While the pathogenesis is not clear, mucosal injury caused by several different mechanisms and local opportunistic infection play significant roles. An association has been recognized between neutropenic colitis and sepsis caused by C. septicum. Patients present with fever, diarrhea, and acute abdominal pain and tenderness often localized in the right lower quadrant. Sonography and CT are helpful in demonstrating colonic wall thickening and pericolic fluid. Peritoneal lavage has been used to exclude perforation in these critically ill patients. Although there has been debate about whether medical or operative management is best, the optimal initial therapy includes supportive care with gastric decompression, fluid and blood product replacement, and broad-spectrum antibiotics. The indications for surgery include continued intestinal bleeding despite correction of coagulopathy and pancytopenia, free intraperitoneal air, and uncontrolled sepsis. At operation, a right colectomy with ileostomy and mucous fistula or, in selected patients, primary anastomosis is the procedure of choice. Timely return of functioning neutrophils and the eventual prognosis of the primary disease are crucial to the overall success or failure of treatment of neutropenic colitis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0039-6109(16)46137-2DOI Listing

Publication Analysis

Top Keywords

neutropenic colitis
16
colitis neutropenic
8
colitis
5
collagenous colitis
4
colitis eosinophilic
4
eosinophilic colitis
4
neutropenic
4
colitis complication
4
complication treatment
4
treatment hematologic
4

Similar Publications

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Ther Adv Drug Saf

January 2025

Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.

Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.

Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF
Article Synopsis
  • A multicenter phase 1b study explored the effectiveness and tolerability of combining spartalizumab with various platinum-doublet chemotherapy regimens in treatment-naïve patients with non-small cell lung cancer (NSCLC) that were not selected based on PD-L1 expression.
  • The study found that the maximum tolerated dose for spartalizumab was 300 mg every 3 weeks, and overall response rates to the treatment generally ranged from 51.5% to 57.6%, indicating a good level of efficacy across different chemotherapy combinations.
  • Notably, patients receiving pemetrexed/cisplatin showed the longest median progression-free survival and overall survival compared to other treatment groups, highlighting the potential of this regimen in
View Article and Find Full Text PDF

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.

Front Pharmacol

July 2024

Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.

Article Synopsis
  • Aprepitant, fosaprepitant, and netupitant are neurokinin-1 receptor antagonists used to prevent nausea and vomiting from chemotherapy, and understanding their side effects can guide clinicians in treatment choices.!
  • Data from the FDA Adverse Event Reporting System showed differing adverse event (AE) profiles for the three drugs; aprepitant was linked to joint deposits, fosaprepitant to seizure-like symptoms, and netupitant had a notable association with death among other unique AEs.!
  • The study highlighted that AEs varied by gender, suggesting clinicians need to consider both common and new emerging AEs, alongside gender differences when prescribing these medications.!
View Article and Find Full Text PDF
Article Synopsis
  • Haematology patients experiencing high-risk neutropenia are susceptible to bloodstream infections linked to mucosal barrier injuries, particularly during episodes of fever.
  • A study involving 416 neutropenic haematology patients identified risk factors for these infections, noting that certain conditions like low MASCC scores and specific fungal colonizations significantly increased risk.
  • Findings revealed that while low citrulline levels at fever onset correlated with candidaemia, they did not indicate the likelihood of bacterial infections; moreover, quinolone antibiotics appeared beneficial.
View Article and Find Full Text PDF

Early and late complications of hematopoietic stem cell transplantation.

Handb Clin Neurol

August 2024

Physiopathology of Human Reproduction Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

As autologous stem cell transplantation (ASCT) is increasingly frequent in some patients with multiple sclerosis (MS), the knowledge of its adverse effects is paramount. Early complications (within 30 from transplantation) are usually due to conditioning regimen and consequent neutropenia. They include infections and noninfectious complications, such as oral and intestinal mucositis, increases in liver enzymes, hemorrhagic cystitis, and worsening of neurologic symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!